Among numerous examples, Suzawa et al. examined the antitumor activity of afatinib, an irreversible epidermal growth factor receptor (EGFR)-HER2 dual inhibitor, in several non-small cell lung cancer (NSCLC) cell lines, including A549, Calu-3, HCC827, NCI-H1299, NCI-H1781, NCI-H1975, NCIH1993, and NCI-H2170, to explore the correlation between the genetic alterations of cells and cell sensitivity to afatinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.